U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C7H5O3.Mg.4H2O
Molecular Weight 370.5923
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MAGNESIUM SALICYLATE

SMILES

c1ccc(c(c1)C(=O)O)O.c1ccc(c(c1)C(=O)[O-])[O-].[Mg+2].O.O.O.O

InChI

InChIKey=NBQBEWAYWAMLJJ-UHFFFAOYSA-L
InChI=1S/2C7H6O3.Mg.4H2O/c2*8-6-4-2-1-3-5(6)7(9)10;;;;;/h2*1-4,8H,(H,9,10);;4*1H2/q;;+2;;;;/p-2

HIDE SMILES / InChI

Molecular Formula C7H6O3
Molecular Weight 138.121
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Mg
Molecular Weight 24.3051
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html

Salicylic acid is obtained from the bark of the white willow and wintergreen leaves, and also prepared synthetically. It has bacteriostatic, fungicidal, and keratolytic actions. Its salts, the salicylates, are used as analgesics. Salicylic acid treats acne by causing skin cells to slough off more readily, preventing pores from clogging up. This effect on skin cells also makes salicylic acid an active ingredient in several shampoos meant to treat dandruff. Use of straight salicylic solution may cause hyperpigmentation on unpretreated skin for those with darker skin types (Fitzpatrick phototypes IV, V, VI), as well as with the lack of use of a broad spectrum sunblock. Subsalicylate in combination with bismuth form the popular stomach relief aid known commonly as Pepto-Bismol. When combined the two key ingredients help control diarrhea, nausea, heartburn, and even gas. It is also very mildly anti-biotic. Salicylic acid directly and irreversibly inhibits the activity of both types of cyclo-oxygenases (COX-1 and COX-2) to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. Salicylate may competitively inhibit prostaglandin formation. Salicylate's antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory mechanisms. Salicylic acid is a key ingredient in many skin-care products for the treatment of acne, psoriasis, calluses, corns, keratosis pilaris, and warts. It works by causing the cells of the epidermis to slough off more readily, preventing pores from clogging up, and allowing room for new cell growth. Because of its effect on skin cells, salicylic acid is used in several shampoos used to treat dandruff. Salicylic acid is also used as an active ingredient in gels which remove verrucas (plantar warts). Salicylic acid inhibits the oxidation of uridine-5-diphosphoglucose (UDPG) competitively with nicotinamide adenosine dinucleotide (NAD) and noncompetitively with UDPG. It also competitively inhibits the transferring of glucuronyl group of uridine-5-phosphoglucuronic acid (UDPGA) to the phenolic acceptor. The wound-healing retardation action of salicylates is probably due mainly to its inhibitory action on mucopolysaccharide synthesis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.48 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1.20346562E12
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1.20346562E12
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1.20346562E12
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1.20346562E12
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

1.35501119E12
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

1.35501119E12
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

1.35501119E12
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
238 min
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SALICYLIC ACID plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
n = 43
Health Status: unhealthy
Condition: Acne vulgaris
Age Group: 23.05 ± 5.7 years
Sex: M+F
Population Size: 43
Sources:
Other AEs: Redness, Scales...
Other AEs:
Redness
Scales
Sources:
AEs

AEs

AESignificanceDosePopulation
Redness
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
n = 43
Health Status: unhealthy
Condition: Acne vulgaris
Age Group: 23.05 ± 5.7 years
Sex: M+F
Population Size: 43
Sources:
Scales
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
n = 43
Health Status: unhealthy
Condition: Acne vulgaris
Age Group: 23.05 ± 5.7 years
Sex: M+F
Population Size: 43
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely
major
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
PubMed

PubMed

TitleDatePubMed
In vitro release studies of methyl salicylate from the ointment bases and the commercial dermatological products.
1990
[Identification and quantification of exogenous metabolites in biological liquids with new development in NMR spectroscopy in one and two dimensions].
1999
[Salicylism and glaucoma: reciprocal augmentation of the toxicity of acetazolamide and acetylsalicylic acid].
1999 Feb
Salicylate attenuates gentamicin-induced ototoxicity.
1999 Jul
Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE).
1999 May
Effects of salicylates on evoked otoacoustic emissions and remote masking in humans.
1999 May-Jun
Microdialysis vs. suction blister technique for in vivo sampling of pharmacokinetics in the human dermis.
1999 Sep
False-high blood salicylate levels in neonates with hyperbilirubinemia.
2000 Dec
Directed control of electroosmotic flow in nonaqueous electrolytes using poly(ethylene glycol) coated capillaries.
2001
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations.
2001
Arabidopsis genome sequence as a tool for functional genomics in tomato.
2001
Nucleotide sequence analysis of 5'-flanking region of salicylate hydroxylase gene, and identification and purification of a LysR-type regulator, SalR.
2001 Apr
Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT.
2001 Apr
Uptake mechanism of valproic acid in human placental choriocarcinoma cell line (BeWo).
2001 Apr 13
Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease.
2001 Apr 17
Hereditary palmoplantar keratoderma (four cases in three generations).
2001 Feb
Induction of wound response gene expression in tomato leaves by ionophores.
2001 Feb
Isolation and preliminary characterization of the medium-chain fatty acid:CoA ligase responsible for activation of short- and medium-chain fatty acids in colonic mucosa from swine.
2001 Feb
Estrogenic activity of phenolic additives determined by an in vitro yeast bioassay.
2001 Feb
Increased leukotriene production by food additives in patients with atopic dermatitis and proven food intolerance.
2001 Feb
Are 2 combined antimicrobial mechanisms better than 1 for the treatment of acne vulgaris? Clinical and antimicrobial results of a topical combination product containing 1% clindamycin and 5% benzoyl peroxide. Introduction.
2001 Feb
A novel pH-sensitive membrane from chitosan--TEOS IPN; preparation and its drug permeation characteristics.
2001 Feb
Molecular responses to aphid feeding in Arabidopsis in relation to plant defense pathways.
2001 Feb
The spinning disc reactor--studies on a novel TiO2 photocatalytic reactor.
2001 Feb
A hot pepper cDNA encoding a pathogenesis-related protein 4 is induced during the resistance response to tobacco mosaic virus.
2001 Feb 28
Guidelines for the management of cutaneous warts.
2001 Jan
Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP.
2001 Jan
Effect of 4-trifluoromethyl derivatives of salicylate on nuclear factor kappaB-dependent transcription in human astrocytoma cells.
2001 Jan
The possibility of achieving an interactive mixture with high dose homogeneity containing an extremely low proportion of a micronised drug.
2001 Jan
Cause of high variability in drug dissolution testing and its impact on setting tolerances.
2001 Jan
Salicylate and cocaine: interactive toxicity during chicken mid-embryogenesis.
2001 Jan 15
Salicylates inhibit T cell adhesion on endothelium under nonstatic conditions: induction of L-selectin shedding by a tyrosine kinase-dependent mechanism.
2001 Jan 15
Characterization of a rice (Oryza sativa L.) Bowman-Birk proteinase inhibitor: tightly light regulated induction in response to cut, jasmonic acid, ethylene and protein phosphatase 2A inhibitors.
2001 Jan 24
Release of salicylic acid, diclofenac acid and diclofenac acid salts from isotropic and anisotropic nonionic surfactant systems across rat skin.
2001 Jan 5
Increased sensitivity to sodium salicylate-induced apoptosis in drug-resistant leukemia L1210 cells.
2001 Jan-Feb
A novel pathway of aerobic benzoate catabolism in the bacteria Azoarcus evansii and Bacillus stearothermophilus.
2001 Jul 6
Signaling mediated by the closely related mammalian Rho family GTPases TC10 and Cdc42 suggests distinct functional pathways.
2001 Mar
Identification of free radicals produced during phacoemulsification.
2001 Mar
Potentiometric determination of acetylsalicylic acid by sequential injection analysis (SIA) using a tubular salicylate-selective electrode.
2001 Mar
In vivo evidence for accelerated generation of hydroxyl radicals in liver of Long-Evans Cinnamon (LEC) rats with acute hepatitis.
2001 Mar 1
ATR-FTIR spectroscopic investigations on the effect of solvents on the permeation of benzoic acid and salicylic acid through silicone membranes.
2001 Mar 23
Use of methyl salicylate as a simulant to predict the percutaneous absorption of sulfur mustard.
2001 Mar-Apr
Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals.
2001 May
Acanthoamoeba attachment to contact lenses.
2001 May
In vitro dermal absorption of methyl salicylate, ethyl parathion, and malathion: first responder safety.
2007 Jun
Patents

Sample Use Guides

adults 18 years and older: apply one patch to affected area and leave in place for up to 8-12 hours; if pain lasts lasts after using the first patch, a second patch may be applied for up to another 8 to 12 hours; use only one patch at a time; do not use more than 2 patches per day; do not use for more 3 days in a row
Route of Administration: Topical
In vitro tests with fresh dermatomed (0.3 to 0.4 mm thick) female breast skin and one leg skin specimen were conducted in Bronaugh flow-through Teflon diffusion cells with three chemicals used to simulate chemical warfare agents: 14C-radiolabeled methyl salicylate (MES), ethyl parathion (PT), and malathion (MT), at three dose levels (2, 20, and 200 mM). Tests were conducted at a skin temperature of 29 degrees C using a brief 30-min exposure to the chemical and a 6.5-h receivor collection period. Rapid absorption of all three chemicals was observed, with MES absorbed about 10-fold faster than PT and MT. For MES, PT, and MT, respectively, there was 32%, 7%, and 12% absorption into the receivor solution at the low dose (2 mM), 17%, 2%, and 3% at the medium dose (20 mM), and 11%, 1%, and 1% at the high dose (200 mM) levels. Including the skin depot for MES, PT, and MT, respectively, there was 40%, 41%, and 21% (low dose), 26%, 16%, and 8% (medium dose), and 13%, 19%, and 10% (high does) absorption.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:55:53 UTC 2021
Edited
by admin
on Fri Jun 25 20:55:53 UTC 2021
Record UNII
41728CY7UX
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MAGNESIUM SALICYLATE
INCI   MI   USP   USP-RS   VANDF   WHO-DD  
INCI  
Official Name English
MAGNESIUM SALICYLATE [VANDF]
Common Name English
MAGNESIUM SALICYLATE TETRAHYDRATE [MI]
Common Name English
MOMENTUM
Brand Name English
MAGNESIUM SALICYLATE [USP MONOGRAPH]
Common Name English
MAGNESIUM SALICYLATE (1:2), TETRAHYDRATE
Common Name English
MAGNESIUM SALICYLATE [USP-RS]
Common Name English
MAGNESIUM SALICYLATE [WHO-DD]
Common Name English
MAGNESIUM SALICYLATE [INCI]
Common Name English
MAGNESIUM SALICYLATE TETRAHYDRATE
Systematic Name English
BACKACHE CAPLETS
Brand Name English
MAGNESIUM, BIS(2-(HYDROXY-.KAPPA.O)BENZOATO-.KAPPA.O)-, HYDRATE (1:4), (T-4)-
Systematic Name English
BAYER SELECT BACKACHE
Brand Name English
Classification Tree Code System Code
DSLD 3106 (Number of products:3)
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
NCI_THESAURUS C257
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL2106755
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
DRUG BANK
DB01397
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
PUBCHEM
5282387
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
NCI_THESAURUS
C66050
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
RXCUI
253186
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
CAS
18917-95-8
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
RXCUI
52364
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
ALTERNATIVE
USP_CATALOG
1374306
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY USP-RS
MERCK INDEX
M7019
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY Merck Index
EVMPD
SUB14444MIG
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
MESH
C496892
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
DRUG CENTRAL
4510
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
FDA UNII
41728CY7UX
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
EPA CompTox
18917-95-8
Created by admin on Fri Jun 25 20:55:53 UTC 2021 , Edited by admin on Fri Jun 25 20:55:53 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY